Premium Ipamorelin

Ipamorelin Research Peptide: Live Price and Evidence Review

> **Research use only. Not for human or animal use.** Ipamorelin is not FDA-approved for therapeutic use. This page is an educational procurement reference for qualified laboratory researchers and contains no dosing or treatment guidance.

Ipamorelin is a synthetic growth hormone secretagogue and ghrelin-receptor agonist used in preclinical and translational research. The current Peptides.SO catalog maps this page to **two in-stock variants from one supplier**. Listed prices are **$13.00** and **$28.99**, with normalized catalog values of **$6.50 and $5.80 per mg**, respectively. Those values are well below the **$41.99 median price per mg across 1,292 in-stock growth-peptide offers** in the current database, but a low catalog price does not establish analytical quality.

Current marketplace snapshot

| Catalog signal | Current value | |---|---:| | In-stock offers | 2 | | Suppliers represented | 1 | | Listed price range | $13.00–$28.99 | | Normalized price range | $5.80–$6.50 per mg | | Growth-peptide category median | $41.99 per mg | | Supplier verification badge | Not present | | Published testing score | 0 |

Both variants are attributed to Pure Peptides UK, and the supplier row records wire transfer as the available payment method. The row does not currently contain structured testing criteria or a verified-supplier badge. Researchers should treat the displayed price as a catalog observation, not as proof of compound identity, purity, sterility, or suitability for a particular assay.

What researchers have studied

Ipamorelin's activity has been examined through the growth hormone secretagogue receptor (GHS-R1a). A ferret study compared ipamorelin and anamorelin in a cisplatin-associated feeding and weight-loss model (PMID 39043357). A separate experimental study used ipamorelin as a peripherally restricted ghrelin-receptor agonist in models of visceral and somatic nociception (PMID 32801950).

Gastrointestinal research includes a randomized phase 2 study in postoperative ileus that did not establish ipamorelin as an approved treatment (PMID 25331030), as well as a rodent study of gastric dysmotility after abdominal surgery (PMID 27186127). These papers document experimental contexts and receptor pharmacology; none validates any current retail product.

Interpreting the price comparison

The $41.99 category median is calculated from current in-stock listings categorized as growth peptides. It spans many molecules, quantities, formulations, and supplier practices, so it is a broad benchmark rather than a like-for-like market value. The two ipamorelin variants also come from the same supplier, meaning the page does not currently offer independent supplier competition.

A defensible procurement decision should confirm the variant quantity, lot number, storage conditions, and analytical documentation. Researchers can inspect GHRP-2 listings, review the GHRP-2 versus GHRP-6 comparison, or use the site comparison tool to explore alternatives. The peptide calculator is intended for laboratory concentration arithmetic only.

Quality checks for laboratory procurement

Ask for a batch-specific certificate of analysis tied to the shipped lot. Identity evidence and purity evidence answer different questions: mass spectrometry can support molecular identity, while an appropriately reported chromatographic method can estimate purity. Neither alone establishes sterility, endotoxin status, residual solvents, water content, or accurate fill mass. Those claims require suitable independent measurements.

Check whether the documentation states the method, date, result, acceptance threshold, and laboratory identity. A generic certificate without a matching lot number offers little traceability. For longitudinal experiments, record supplier, lot, receipt date, storage conditions, and reconstitution solvent so that unexplained batch effects can be investigated.

Ipamorelin and related secretagogues

Ipamorelin and GHRP-2 both engage growth hormone secretagogue pathways, but published studies use them in different models and conditions. Receptor-level similarity does not justify substituting one compound for another in an established protocol. If combination research is under consideration, the stack builder can organize compound records, but it does not assess safety or provide administration instructions.

Frequently asked questions

Is ipamorelin FDA-approved?

No. Ipamorelin is not FDA-approved for therapeutic use. It should remain within properly controlled research settings.

Why are the listed prices below the category median?

The category median covers many different growth-peptide molecules and package formats. The comparison highlights a catalog difference, not a quality judgment or a guarantee of equivalent quantity.

Does Peptides.SO verify the two current variants?

The supplier record currently has no verified badge, no structured testing criteria, and a testing score of zero. Researchers should independently obtain and evaluate lot-specific analytical evidence.

Do the PubMed studies prove that commercial ipamorelin works?

No. The cited studies describe defined experimental materials and conditions. They do not authenticate current catalog lots or support unsupervised use.

Research-use boundary

Ipamorelin should be handled only by qualified personnel under an institutionally approved laboratory protocol. This page does not provide medical advice, veterinary advice, dosing instructions, or a recommendation to purchase or administer the compound.